(Q48362177)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

M Kirsch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

K Geiger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

B Klink

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

E Leipnitz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

T Pinzer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

S Soucek

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

E Schrock

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

G Schackert

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

D Krex

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

27 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

325-333

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23015095%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11060-012-0977-2

9 March 2020

exact match

0 references

cites work

Genetic pathways to primary and secondary glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Epigenetic markers in human gliomas: prospects for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Molecular classification of low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Optimal role of temozolomide in the treatment of malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2

Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0977-2